TuHURA Biosciences (HURA) Other Accumulated Expenses (2023 - 2024)
TuHURA Biosciences (HURA) posted quarterly Other Accumulated Expenses of $50000.0 for Q3 2024, down 85.21% year-over-year from $338000.0 in Q4 2023, and down 3.85% quarter-over-quarter from $52000.0 in Q2 2024.
TuHURA Biosciences (HURA) Other Accumulated Expenses (2023 - 2024) Analysis & Trends
TuHURA Biosciences' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $50000.0 for Q3 2024.
- In Q3 2024, Other Accumulated Expenses fell 85.21% year-over-year to $50000.0; the TTM figure through Sep 2024 stood at $50000.0 (down 85.21% YoY), while the FY2024 annual figure was $52000.0, down 82.55% from the prior year.
- Other Accumulated Expenses for Q3 2024 stood at $50000.0, down from $52000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $338000.0 in Q3 2023, with the low at $50000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 338,000.00 |
| Jun 30, 2023 | 298,000.00 |